胡適 教授

第二軍醫(yī)大學(xué)基礎(chǔ)醫(yī)學(xué)部

胡適，男，第二軍醫(yī)大學(xué)基礎(chǔ)醫(yī)學(xué)院教授，碩士生導(dǎo)師。研究方向?yàn)榭贵w藥物工程和新型細(xì)胞治療技術(shù)?，F(xiàn)主持國家自然科學(xué)基金新型冠狀病毒專項(xiàng)、面上項(xiàng)目、重大新藥創(chuàng)制子課題等十余項(xiàng)各類科研項(xiàng)目。近五年內(nèi)以通訊作者在Science Translational Medicine，Nature Communications、Clinical Cancer Research等國際刊物上發(fā)表SCI論文二十余篇，申請(qǐng)中國專利19項(xiàng)，PCT專利8項(xiàng)。主要研究方向包括新型抗體工程技術(shù)和細(xì)胞治療技術(shù)的應(yīng)用研究。

代表論著：

(1) Shi Hu^?*, Wenyan Fu^?, Tian Li, Ying Tang, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Yongji Yang, and Changhai Lei*. Antagonism of EGFR and Notch Limits Acquired Resistance to EGFR Inhibitors and Radiation by Decreasing Tumor-Initiating Cell Frequency. Science Translation Medicine, 2017. 9(380): p. eaag0339.

(2) Shi Hu^?*, Wenyan Fu^?, Weihao Xu^?, Yang Yang, Melissa Cruz, Sandra D Berezov, Daniel Jorissen, Hiroaki Takeda, and Wangdong Zhu*, Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer research, 2015. 75(1): p. 159-170.

(3) Shi Hu^?*, Haibin Dai^?, Tian Li^?, Ying Tang, Wenyan Fu, Qingning Yuan, FeifeiWang, Gaojian Lv, Yuanyuan Lv, Xiaoyan Fan, Sheng Zhang, Ruobing Jin, Yafeng Shen, Fangxing Lin, Xuting Ye, Min Ding, Yongji Yang, and Changhai Lei*. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Cancer Letters, 2016, 382(1): 32-43.

(4) Shi Hu^?, Shuaiyi Liang^?, Huaizu Guo, Dapeng Zhang, Hui Li, Xiaoze Wang, Weili Yang, Weizhu Qian, Sheng Hou, Hao Wang, Yajun Guo*, and Zhiyong Lou*, Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View. Journal of Biological Chemistry, 2013. 288(38): p. 27059-27067.